Sanofi's Lixisenatide Shows Challenges Of Being Late Entrant In Class
Executive Summary
Safety and efficacy of what would be sixth GLP-1 agonist seem solid, but FDA advisory committee notes concerns about allergic reactions, dosing and relative effectiveness.
You may also be interested in...
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
The latest drug development news and highlights from our FDA Performance Tracker.
Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros
The latest drug development news and highlights from our FDA Performance Tracker